E17 General Principles for Planning and Design of Multi-Regional Clinical Trials; International Council for Harmonisation; Draft Guidance for Industry; Availability, 62506-62508 [2016-21689]
Download as PDF
62506
Federal Register / Vol. 81, No. 175 / Friday, September 9, 2016 / Notices
asabaliauskas on DSK3SPTVN1PROD with NOTICES
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Katherine Collins, Center for Tobacco
Products, Food and Drug
Administration, Document Control
Center, Bldg. 71, Rm. G335, 10903 New
Hampshire Ave., Silver Spring, MD
20993–2000, 1–877–287–1373, email:
AskCTP@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
We are announcing the availability of
a revised draft guidance for industry
entitled ‘‘Health Document Submission
Requirements for Tobacco Products.’’
We are issuing this draft guidance
consistent with our good guidance
practices (GGP) regulation (21 CFR
10.115). The draft guidance, when
finalized, is intended to assist persons
making certain document submissions
to FDA as required by the Tobacco
Control Act.
The Tobacco Control Act, enacted on
June 22, 2009, amends the FD&C Act
and provides FDA with the authority to
regulate the manufacture, marketing,
and distribution of tobacco products to
protect the public’s health (Pub. L. 111–
31). Among other things, the Tobacco
Control Act adds section 904(a)(4) to the
FD&C Act (21 U.S.C. 387d(a)(4)),
requiring each tobacco product
manufacturer or importer, or agents
thereof to submit all documents
developed after June 22, 2009, that
relate to any ‘‘health, toxicological,
behavioral, or physiological effects of
current or future tobacco products, their
constituents (including smoke
constituents), ingredients, components,
and additives.’’
The revised draft guidance includes
guidance for manufacturers or importers
of products that are newly deemed as
tobacco products that are subject to
Chapter IX of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act).
Cigarettes, cigarette tobacco, roll-yourown tobacco, and smokeless tobacco
were immediately subject to the tobacco
provisions of the FD&C Act, including
section 904(a)(4), and to FDA’s
regulatory authority. As for other types
of tobacco products, section 901(b) of
the FD&C Act (21 U.S.C. 387a) grants
FDA authority to deem those products
subject to the law as well. Pursuant to
that authority, FDA issued a rule
deeming all other products that meet the
statutory definition of ‘‘tobacco
product’’, set forth in section 201(rr) of
the FD&C Act, except for accessories of
those products, as subject to the FD&C
Act (81 FR 28974). FDA published the
VerDate Sep<11>2014
17:11 Sep 08, 2016
Jkt 238001
final rule on May 10, 2016 (81 FR
28974), and it became effective on
August 8, 2016. Manufacturers and
importers of tobacco products that have
been deemed subject to the FD&C Act
are now required to comply with
Chapter IX of the FD&C Act, including
section 904(a)(4).
II. Significance of Guidance
FDA is issuing this revised draft
guidance consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). The draft guidance, when
finalized, represents the current
thinking of FDA on health document
submission requirements. It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
II. Paperwork Reduction Act of 1995
This revised draft guidance also refers
to previously approved collections of
information found in FDA statute. The
revised draft guidance includes
information and recommendations for
how to provide health document
submissions. The collections of
information in section 904(a)(4) of the
FD&C Act have been approved under
OMB control number 0910–0654.
IV. Electronic Access
Persons with access to the Internet
may obtain an electronic version of the
draft guidance at either https://
www.regulations.gov or https://
www.fda.gov/TobaccoProducts/
Labeling/RulesRegulationsGuidance/
default.htm.
Dated: August 31, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–21686 Filed 9–8–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–D–2567]
E17 General Principles for Planning
and Design of Multi-Regional Clinical
Trials; International Council for
Harmonisation; Draft Guidance for
Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
guidance entitled ‘‘E17 General
Principles for Planning and Design of
Multi-Regional Clinical Trials.’’ The
draft guidance was prepared under the
auspices of the International Council for
Harmonisation (ICH), formerly the
International Conference on
Harmonisation. The draft guidance
describes general principles for
planning and designing multi-regional
clinical trials (MRCT). MRCTs
conducted according to the guidance
will investigate treatment effects in
overall populations with multiple
ethnic factors (intrinsic and extrinsic
factors as described in the ICH guidance
entitled ‘‘E5 Ethnic Factors in the
Acceptability of Foreign Clinical Data’’
(E5 guidance)) and evaluate the
consistency of treatment effects across
populations. The draft guidance is
intended to increase the acceptability of
data from MRCTs as the primary source
of evidence supporting marketing
approval in global regulatory
submissions and to thereby facilitate
more efficient drug development and
earlier access to medicines.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by November 8,
2016.
ADDRESSES: You may submit comments
as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
E:\FR\FM\09SEN1.SGM
09SEN1
Federal Register / Vol. 81, No. 175 / Friday, September 9, 2016 / Notices
asabaliauskas on DSK3SPTVN1PROD with NOTICES
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–D–2567 for ‘‘E17 General
Principles for Planning and Design of
Multi-Regional Clinical Trials;
International Council for
Harmonisation; Draft Guidance for
Industry; Availability.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
VerDate Sep<11>2014
17:11 Sep 08, 2016
Jkt 238001
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
Submit written requests for single
copies of this guidance to the Division
of Drug Information, Center for Drug
Evaluation and Research (CDER), Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002; or the Office of Communication,
Outreach and Development, Center for
Biologics Evaluation and Research
(CBER), Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71,
Rm. 3128, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your requests. The guidance may also be
obtained by mail by calling CBER at 1–
800–835–4709 or 240–402–8010. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Aloka
Chakravarty, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 21, Rm. 3514, Silver Spring,
MD 20993–0002, 301–796–1655; or
Douglas R. Pratt, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3066,
Silver Spring, MD 20993–0002, 301–
796–2640.
Regarding the ICH: Amanda Roache,
Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 51, Rm. 1176, Silver Spring,
MD 20993–0002, 301–796–4548.
SUPPLEMENTARY INFORMATION:
I. Background
In recent years, many important
initiatives have been undertaken by
regulatory authorities and industry
associations to promote international
harmonization of regulatory
requirements. FDA has participated in
many meetings designed to enhance
harmonization and is committed to
seeking scientifically based harmonized
technical procedures for pharmaceutical
development. One of the goals of
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
62507
harmonization is to identify and then
reduce differences in technical
requirements for drug development
among regulatory agencies.
ICH was organized to provide an
opportunity for harmonization
initiatives to be developed with input
from both regulatory and industry
representatives. FDA also seeks input
from consumer representatives and
others. ICH is concerned with
harmonization of technical
requirements for the registration of
pharmaceutical products for human use
among regulators around the world. The
six founding members of the ICH are the
European Commission; the European
Federation of Pharmaceutical Industries
Associations; the Japanese Ministry of
Health, Labour, and Welfare; the
Japanese Pharmaceutical Manufacturers
Association; CDER and CBER, FDA; and
the Pharmaceutical Research and
Manufacturers of America. The
Standing Members of the ICH
Association include Health Canada and
Swissmedic. Any party eligible as a
Member in accordance with the ICH
Articles of Association can apply for
membership in writing to the ICH
Secretariat. The ICH Secretariat, which
coordinates the preparation of
documentation, operates as an
international nonprofit organization and
is funded by the Members of the ICH
Association.
The ICH Assembly is the overarching
body of the Association and includes
representatives from each of the ICH
members and observers.
In June 2016, the ICH Assembly
endorsed the draft guidance entitled
‘‘E17 General Principles for Planning
and Design of Multi-Regional Clinical
Trials’’ and agreed that the guidance
should be made available for public
comment. The draft guidance is the
product of the Efficacy Expert Working
Group of the ICH. Comments about this
draft will be considered by FDA and the
Efficacy Expert Working Group.
The draft guidance provides guidance
on general principles for planning and
designing MRCTs. Drug development
has been globalized, and MRCTs for
regulatory submission have widely been
conducted in ICH regions and beyond.
Regulatory agencies are currently facing
some challenges in evaluating data from
MRCTs for drug approval, and ICH is
developing this harmonized
international guidance to promote the
appropriate conduct of MRCTs and to
focus especially on scientific issues in
planning and designing MRCTs. This
new guidance will complement the E5
guidance on MRCTs and facilitate
MRCT data acceptance by multiple
regulatory agencies.
E:\FR\FM\09SEN1.SGM
09SEN1
62508
Federal Register / Vol. 81, No. 175 / Friday, September 9, 2016 / Notices
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on ‘‘E17 General Principles for Planning
and Design of Multi-Regional Clinical
Trials.’’ It does not establish any rights
for any person and is not binding on
FDA or the public. You can use an
alternative approach if it satisfies the
requirements of the applicable statutes
and regulations.
II. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.regulations.gov, https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, or https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/Guidances/default.htm.
Dated: September 2, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–21689 Filed 9–8–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
Science Advisory Board to the
National Center for Toxicological
Research Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Science Advisory Board
(SAB) to the National Center for
Toxicological Research (NCTR). The
general function of the committee is to
provide advice and recommendations to
the Agency on FDA’s regulatory issues.
At least one portion of the meeting will
be closed to the public.
DATES: The meeting will be held on
November 1, 2016, from 8 a.m. to 5:30
p.m., and on November 2, 2016, from 8
a.m. to 11:40 a.m.
ADDRESSES: Crowne Plaza Hotel, 201 S.
Shackleford Rd., Little Rock, AR 72211.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:11 Sep 08, 2016
Jkt 238001
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
Donna Mendrick, National Center for
Toxicological Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 2208, Silver Spring,
MD 20993–0002, 301–796–8892 or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On November 1, 2016, the
SAB Chair will welcome the
participants, and the NCTR Director will
provide a Center-wide update on
scientific initiatives and
accomplishments during the past year.
The SAB will be presented with an
overview of the Division of
Bioinformatics and Biostatistics
Subcommittee and the Subcommittee
Site Visit Report and a response to this
review. There will be the public
comment session and an update from
the NCTR Research Divisions.
On November 2, 2016, the Center for
Biologics and Evaluation and Research,
Center for Drug Evaluation and
Research, Center for Devices and
Radiological Health, Office of Food and
Veterinary Medicine, Center for Tobacco
Products, and the Center for Veterinary
Medicine will each briefly discuss their
center-specific research strategic needs
and potential areas of collaboration.
Following an open discussion of all
the information presented, the open
session of the meeting will close so the
SAB members can discuss personnel
issues at NCTR at the end of each day.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: On November 1, 2016,
from 8 a.m. to 5:30 p.m., and November
2, 2016, from 8 a.m. to 11:40 a.m., the
meeting is open to the public. Interested
persons may present data, information,
or views, orally or in writing, on issues
pending before the committee. Written
submissions may be made to the contact
person on or before October 25, 2016.
Oral presentations from the public will
be scheduled on November 1, 2016,
between approximately 1:15 p.m. to
2:15 p.m. Those individuals interested
in making formal oral presentations
should notify the contact person and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation on
or before October 17, 2016. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
October 18, 2016.
Closed Committee Deliberations: On
November 1, 2016, from 5:30 p.m. to 6
p.m., and November 2, 2016, from 11:40
a.m. to 12:15 p.m., the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). This
portion of the meeting will be closed to
permit discussion of information
concerning individuals associated with
the research programs at NCTR.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Donna
Mendrick at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
E:\FR\FM\09SEN1.SGM
09SEN1
Agencies
[Federal Register Volume 81, Number 175 (Friday, September 9, 2016)]
[Notices]
[Pages 62506-62508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21689]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-D-2567]
E17 General Principles for Planning and Design of Multi-Regional
Clinical Trials; International Council for Harmonisation; Draft
Guidance for Industry; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a draft guidance entitled ``E17 General Principles
for Planning and Design of Multi-Regional Clinical Trials.'' The draft
guidance was prepared under the auspices of the International Council
for Harmonisation (ICH), formerly the International Conference on
Harmonisation. The draft guidance describes general principles for
planning and designing multi-regional clinical trials (MRCT). MRCTs
conducted according to the guidance will investigate treatment effects
in overall populations with multiple ethnic factors (intrinsic and
extrinsic factors as described in the ICH guidance entitled ``E5 Ethnic
Factors in the Acceptability of Foreign Clinical Data'' (E5 guidance))
and evaluate the consistency of treatment effects across populations.
The draft guidance is intended to increase the acceptability of data
from MRCTs as the primary source of evidence supporting marketing
approval in global regulatory submissions and to thereby facilitate
more efficient drug development and earlier access to medicines.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by November 8, 2016.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a
[[Page 62507]]
written/paper submission and in the manner detailed (see ``Written/
Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-D-2567 for ``E17 General Principles for Planning and Design of
Multi-Regional Clinical Trials; International Council for
Harmonisation; Draft Guidance for Industry; Availability.'' Received
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
Submit written requests for single copies of this guidance to the
Division of Drug Information, Center for Drug Evaluation and Research
(CDER), Food and Drug Administration, 10001 New Hampshire Ave.,
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002; or the
Office of Communication, Outreach and Development, Center for Biologics
Evaluation and Research (CBER), Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. The guidance may also be obtained by mail by calling
CBER at 1-800-835-4709 or 240-402-8010. See the SUPPLEMENTARY
INFORMATION section for electronic access to the guidance document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Aloka Chakravarty, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 21, Rm. 3514, Silver Spring, MD 20993-0002, 301-
796-1655; or Douglas R. Pratt, Center for Biologics Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
71, Rm. 3066, Silver Spring, MD 20993-0002, 301-796-2640.
Regarding the ICH: Amanda Roache, Center for Drug Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, Rm. 1176, Silver Spring, MD 20993-0002, 301-796-4548.
SUPPLEMENTARY INFORMATION:
I. Background
In recent years, many important initiatives have been undertaken by
regulatory authorities and industry associations to promote
international harmonization of regulatory requirements. FDA has
participated in many meetings designed to enhance harmonization and is
committed to seeking scientifically based harmonized technical
procedures for pharmaceutical development. One of the goals of
harmonization is to identify and then reduce differences in technical
requirements for drug development among regulatory agencies.
ICH was organized to provide an opportunity for harmonization
initiatives to be developed with input from both regulatory and
industry representatives. FDA also seeks input from consumer
representatives and others. ICH is concerned with harmonization of
technical requirements for the registration of pharmaceutical products
for human use among regulators around the world. The six founding
members of the ICH are the European Commission; the European Federation
of Pharmaceutical Industries Associations; the Japanese Ministry of
Health, Labour, and Welfare; the Japanese Pharmaceutical Manufacturers
Association; CDER and CBER, FDA; and the Pharmaceutical Research and
Manufacturers of America. The Standing Members of the ICH Association
include Health Canada and Swissmedic. Any party eligible as a Member in
accordance with the ICH Articles of Association can apply for
membership in writing to the ICH Secretariat. The ICH Secretariat,
which coordinates the preparation of documentation, operates as an
international nonprofit organization and is funded by the Members of
the ICH Association.
The ICH Assembly is the overarching body of the Association and
includes representatives from each of the ICH members and observers.
In June 2016, the ICH Assembly endorsed the draft guidance entitled
``E17 General Principles for Planning and Design of Multi-Regional
Clinical Trials'' and agreed that the guidance should be made available
for public comment. The draft guidance is the product of the Efficacy
Expert Working Group of the ICH. Comments about this draft will be
considered by FDA and the Efficacy Expert Working Group.
The draft guidance provides guidance on general principles for
planning and designing MRCTs. Drug development has been globalized, and
MRCTs for regulatory submission have widely been conducted in ICH
regions and beyond. Regulatory agencies are currently facing some
challenges in evaluating data from MRCTs for drug approval, and ICH is
developing this harmonized international guidance to promote the
appropriate conduct of MRCTs and to focus especially on scientific
issues in planning and designing MRCTs. This new guidance will
complement the E5 guidance on MRCTs and facilitate MRCT data acceptance
by multiple regulatory agencies.
[[Page 62508]]
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on ``E17 General
Principles for Planning and Design of Multi-Regional Clinical Trials.''
It does not establish any rights for any person and is not binding on
FDA or the public. You can use an alternative approach if it satisfies
the requirements of the applicable statutes and regulations.
II. Electronic Access
Persons with access to the Internet may obtain the document at
https://www.regulations.gov, https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, or
https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
Dated: September 2, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-21689 Filed 9-8-16; 8:45 am]
BILLING CODE 4164-01-P